# Therorna

Source: https://onco.cc/companies/therorna/  
OnCo record `therorna` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Therorna builds medicines from circular RNA, a more stable form of RNA. Its first cancer product is a therapeutic vaccine for people whose cancer is driven by the HPV-16 virus and has come back or spread.

## Summary

Therorna Inc. (Yuanyin (Beijing) Biotechnology Co., Ltd.), founded in April 2021 according to the company, is based in Haidian District, Beijing, with a site in the Shanghai Free Trade Zone. It develops preventive and therapeutic medicines on a circular RNA (circRNA) platform. Its phase 1 dose-escalation study (NCT07081984) tests TI-0093, which the registry describes as a therapeutic tumour vaccine given by intramuscular injection on five occasions, in recurrent or metastatic HPV-16 positive solid tumours including head and neck squamous cell carcinoma and cervical cancer, at a site in Shanghai. Its first registered cancer trial, NCT07081984, was posted on ClinicalTrials.gov in July 2025.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Yuanyin (Beijing) Biotechnology
- HQ: Beijing
- Type: biotech
- Website: https://www.therorna.com/

## Notes

- Founding date and addresses from the company's Chinese 'company overview' and contact text, read on 29 October 2026.
- The pages read do not state that TI-0093 itself is a circRNA product, although the company's platform is circRNA; this is an inference and should be checked.
- Investors are not listed on the page read, and no financing amount was read.

## Sources

- Official website: https://www.therorna.com/
- Company overview (Chinese): https://www.therorna.com/about.html
- ClinicalTrials.gov: phase 1 trial of TI-0093 (NCT07081984): https://clinicaltrials.gov/study/NCT07081984

## Connected records

- cancers: [HPV-positive oropharyngeal cancer](https://onco.cc/cancers/hpv-positive-oropharyngeal-cancer/), [Recurrent or metastatic cervical cancer](https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/), [Recurrent or metastatic head and neck squamous cell carcinoma](https://onco.cc/cancers/recurrent-metastatic-hnscc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [Self-amplifying and circular RNA therapeutics](https://onco.cc/technologies/self-amplifying-rna/)

---
JSON: https://onco.cc/api/v1/entities/therorna.json